STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of the EVO family of Implantable
Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia,
and SharpeVision, a premier ophthalmology group with clinics in
Seattle, Chicago and Austin, today announced a strategic agreement
to provide EVO ICL lenses as a first choice for patients seeking
visual freedom from contact lenses and glasses.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240123947715/en/
Dr. Matthew Sharpe, SharpeVision (Photo:
Business Wire)
STAAR Surgical and SharpeVision will collaborate on marketing
and education activities to elevate awareness of EVO ICL and
significantly increase availability of the lenses to all qualified
patients in SharpeVision clinics. STAAR Surgical will also provide
additional practice development and clinical support. The initial
stage of the collaboration includes a target purchase amount of
1,000 ICL units annually, which represents approximately 25% of the
group’s refractive procedure volume.
“We are pleased to announce SharpeVision as a new partner under
our U.S. Highway 93 go-to-market program initiated in October 2023.
Dr. Sharpe is a leading refractive surgeon known for his LASIK
clinics who sees the advantage of EVO ICL over laser-based vision
correction for his patients and practice alike,” said Tom Frinzi,
President and CEO of STAAR Surgical. “Our collaboration will
further increase awareness of the patient and practice benefits of
EVO ICL, which provides exceptional vision day and night and does
not cause dry eye syndrome.”1,2,3
The EVO ICL lens can permanently correct vision without removing
corneal tissue and, if desired, is removable by a doctor for added
peace of mind. The lens gives the patient flexibility for the
future, while also helping to eliminate the hassles of glasses and
contact lenses now.
“As surgeons like me get more time and experience with any
technology, our level of comfort and proficiency grows,” shared
Matthew Sharpe, MD, founder and surgeon, SharpeVision. “Given the
outstanding outcomes, EVO ICL is now my first recommendation for
patients seeking refractive vision correction. The EVO procedure
solves many of the limitations we see in LASIK and PRK laser vision
correction surgery including postoperative ocular surface dryness
and corneal weakening/ectasia. I have implanted the EVO ICL lenses
in more than 600 eyes over the past two years including those of my
own son. My son still talks about the freedom of life without
glasses or contact lenses and the superb quality of his new
vision.”
Warren Foust, Chief Operating Officer of STAAR Surgical stated,
“EVO ICL has demonstrated proven clinical benefits for patients in
the U.S. with refractive error -3.0 diopters and above. As U.S.
surgeons continue to move down the diopter curve, we believe that
for patients -6.0 diopters and above, EVO ICL will increasingly
become their preferred choice. We are proud to partner with
SharpeVision as they make EVO ICL available to more patients.”
For more information about EVO Implantable Collamer® Lenses,
please visit https://evoicl.com.
References
- EVO/EVO+ ICL DFU and PIB.
- Martinez-Plazs E, Lopez-Miguel A, Lopez-De La Rosa A, et al.
Effect of the EVO+ Visian Phakic Implantable Collamer Lens on
Visual Performance and Quality of Vision and Life, Am J Ophthalmol
2021;226: 117–125.
- Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid
Measurements as Dry-Eye Score in Patients After LASIK and ICL
Surgery. Presented at American Society of Cataract and Refractive
Surgery (ASCRS) 2012.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 40 years, designs, develops, manufactures and markets
implantable lenses for the eye. These lenses are intended to
provide visual freedom for patients, lessening or eliminating the
reliance on glasses or contact lenses. All of these lenses are
foldable, which permits the surgeon to insert them through a small
incision. STAAR’s lens used in refractive surgery is called an
Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™
product line. More than 2,500,000 ICLs have been sold to date and
STAAR markets these lenses in over 75 countries. To learn more
about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
About SharpeVision
SharpeVision is a premier ophthalmology group that brings the
best refractive and cataract surgeons, technologies and correction
procedures to our patients, all for the best price. SharpeVision
clinics offer EVO ICL, LASIK, PRK and cataract procedures that are
designed to address the three vision milestones of adult life –
ocular maturity (prescription stability and the opportunity to
correct nearsightedness, farsightedness and astigmatism);
dysfunctional lens syndrome (presbyopia ages 45-60); and cataract
development (ages 60+). SharpeVision’s goal is to restore the
ability to see clearly which is an essential part of being the best
version of yourself. SharpeVision currently operates clinics in
Austin, TX, Chicago, IL and Seattle-Bellevue, WA. To learn more,
please visit www.sharpe-vision.com.
Important Safety Information for EVO
ICL
The EVO Visian ICL lens is intended to correct/reduce
nearsightedness between -3.0 D up to -20.0 D and treat astigmatism
from 1.0 D to 4.0 D. If you have nearsightedness within these
ranges, EVO Visian ICL surgery may improve your distance vision
without eyeglasses or contact lenses. Because the EVO Visian ICL
corrects for distance vision, it does not eliminate the need for
reading glasses, you may require them at some point, even if you
have never worn them before. Since implantation of the EVO Visian
ICL is a surgical procedure, before considering EVO Visian ICL
surgery you should have a complete eye examination and talk with
your eye care professional about EVO Visian ICL surgery, especially
the potential benefits, risks, and complications. You should
discuss the time needed for healing after surgery. Complications,
although rare, may include need for additional surgical procedures,
inflammation, loss of cells from the back surface of the cornea,
increase in eye pressure, and cataracts. You should NOT have EVO
Visian ICL surgery if your doctor determines that 1) the shape of
your eye is not appropriate, 2) you do not meet the minimum
endothelial cell density for your age at the time of implantation,
3) you have moderate to severe glaucoma, 4) your vision is not
stable; or 5) if you are pregnant or nursing.
For additional information with potential benefits, risks and
complications please visit evoicl.com.
Safe Harbor
All statements that are not statements of historical fact are
forward-looking statements, including statements about any of the
following: any financial projections (including sales), plans,
strategies, and objectives of management for 2024 and beyond or
prospects for achieving such plans, expectations for sales,
revenue, margin, expenses or earnings, and any statements of
assumptions underlying any of the foregoing, including those
relating to financial performance in the upcoming quarter, fiscal
year 2024 and beyond. Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements include risks and uncertainties related
to global economic conditions, as well as the factors set forth in
the Company’s Annual Report on Form 10-K for the year ended
December 30, 2022 under the caption “Risk Factors,” which is on
file with the Securities and Exchange Commission and available in
the “Investor Information” section of the company’s website under
the heading “SEC Filings.” We disclaim any intention or obligation
to update or revise any financial projections or forward-looking
statement due to new information or events. These statements are
based on expectations and assumptions as of the date of this press
release and are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those
described in the forward-looking statements. The risks and
uncertainties include the following: global economic conditions;
the impact of COVID-19; the discretion of regulatory agencies to
approve or reject existing, new or improved products, or to require
additional actions before or after approval, or to take enforcement
action; international trade disputes and substantial dependence on
demand from Asia; and the willingness of surgeons and patients to
adopt a new or improved product and procedure.
We intend to use our website as a means of disclosing material
non-public information and for complying with our disclosure
obligations under Regulation FD. Such disclosures will be included
on our website in the ‘Investor Relations’ sections. Accordingly,
investors should monitor such portions of our website, in addition
to following our press releases, SEC filings and public conference
calls and webcasts.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240123947715/en/
Investors & Media Brian Moore Vice President,
Investor Relations and Corporate Development (626) 303-7902, Ext.
3023 bmoore@staar.com
Grafico Azioni STAAR Surgical (NASDAQ:STAA)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni STAAR Surgical (NASDAQ:STAA)
Storico
Da Mar 2024 a Mar 2025
